A case of Fabry's disease in a patient with no α-galactosidase A activity caused by a single amino acid substitution of Pro-40 by Ser  by Koide, Tsuyoshi et al.
Volume 259, number 2, 353-356 FEB 07999 January 1990 
A case of Fabry’s disease in a patient with no a-galactosidase A activity 
caused by a single amino acid substitution of Pro-40 by Ser 
Tsuyoshi Koide*, Masahiro Ishiura *, Kunimitu Iwai”, Michitoshi Inoue+, Yasufumi Kanedat, 
Yoshio Okadat and Tsuyoshi U&da*+ 
*Division of Cell Fusion, Department of Cell Biology, National Institute for Basic Biology, Myodaijicho, Okazaki, Aichi 444, “The 
First Department of Medicine, Osaka University Medical School, Nakanoshima, Kitaku. Osaka 530, ‘Department of Medical 
Information Science, Osaka University Medical School, Nakanoshima, Kitaku, Osaka 530 and tlnstitute for Molecular and Cellular 
Biology, Osaka University, Yamada-oka. Suita, Osaka 565, Japan 
We analyzed a male patient with Fabry’s disease who had no activity of the lysosomal hydrolase a-galactosidase A (a-GalA) and female members 
of his family. We cloned a cDNA that encoded the mutant a-GalA, determined its nucleotide sequence, and found two nucleotide differences between 
the mutant and the wild-type cDNAs. Although one difference was silent, the other difference, aC-to-T transition at nucleotide number 118, resulted 
in an amino acid substitution of Pro-40 by Ser. A transient expression assay demonstrated that this missense mutation was the cause of the deficiency 
of a-GalA activity in the patient. In vitro mutagenesis experiments demonstrated that Pro-40 is critical for the appearance of a-GalA activity. 
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1. INTRODUCTION 
FD is an X-linked, recessive, genetic disease which is 
caused by a deficiency in the activity of the lysosomal 
hydrolase cu-GalA (EC 3.2.1.22) [11. The absence of this 
enzymatic activity causes the accumulation of glyco- 
sphingolipids, such as globotriaosylceramide and 
galabiosylceramide, primarily in the lysosomes of the 
vascular endothelia and in plasma [l]. a-GalA is syn- 
thesized as a 50 kDa precursor glycopeptide and pro- 
cessed to a 46 kDa glycopeptide, and the mature enzyme 
is a homodimer of the 46 kDa subunits [l]. Recently, 
the nucleotide sequences of a cDNA and a genomic gene 
encoding human a-GalA were determined [2,3]. 
However, the functional domains of cu-GalA protein 
that are required for its maturation, including glyco- 
sylation and modification of the sugar residues, 
transport into lysosomes, dimerization, stabilization, 
and the enzymatic activity per se are poorly understood. 
The accumulation of missense mutations in a-GalA 
protein by an analysis of many patients with FD should 
be useful for characterization of the functional do- 
mains. Only one missense mutation that results in the 
deficiency of cu-GalA activity has been reported thus far 
141. 
We report that a single amino acid substitution of 
Pro-40 by Ser resulted in the deficiency of a-GalA ac- 
tivity in a male patient with FD and we describe results 
of in vitro mutagenesis experiments that demonstrate 
that the Pro-40 residue is critical for the appearance of 
the enzymatic activity. 
2. MATERIALS AND METHODS 
2.1. Cell cultures 
Skin fibroblasts were isolated from the forearms of a patient with 
FD (FIS cells) and a normal male volunteer (NSF cells). They were 
transformed with the gene for the large T-antigen of SV40 and main- 
tained in cu-MEM supplemented with 10% FCS. 
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2.2. Preparation and analysis of RNA, construction of cDNA 
library, and nucleotide sequencing 
This paper is dedicated to the late Professor Tsuyoshi Uchida, who in- 
itiated and organized this project 
Abbreviations: a-GalA, cu-galactosidase A; (Y-MEM, alpha modifica- 
tion of Eagle’s minimum essential medium; EF2, elongation factor 2; 
FCS, fetal calf serum; FD, Fabry’s disease; PCR, polymerase chain 
reaction; Pre-40, Pro at the 40th amino acid residue of an a-GalA 
precursor protein which has a signal sequence of 3 1 amino acids at its 
amino terminus; SV40, Simian virus 40 
These sequence data will appear in the EMBL/GenBank/DDBJ 
Nucleotide Sequence Databases under the accession number Xl6889 
Preparation and analysis by Northern blotting of poly(A)+ RNAs 
were carried out as described previously [5]. A hgtl 1 cDNA library 
was constructed from the poly(A) + RNA of FIS cells by a standard 
procedure [5]. We isolated a full-length cDNA that encoded o-GalA 
from the library by plaque hybridization, using two “P-labeled 
30-mer oligonucleotides, RAG1 (5’-GAGTACACAATGCTTCTG- 
CCAGTCCTATTC-3 ’ ) and RAG2 (5 ’ -AAGGTTGCACATGAAG- 
CGCTCCCAGTGCAG-3 ‘) and RAG2 (5 ’ AAGGTTGCACATG- 
AAGCGCTCCCAGTGCAG-3 ‘), as hybridization probes. The 
EcoRI insert of hAGFl1 was subcloned into the EcoRI site of 
pUCl18 (pAGF1 l-5). Nucleotide sequences were determined by the 
chain termination method [5]. 
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2.3. Analysis of the a-GalA gene in genomic DNA by the PCR 
Genomic DNAs were prepared from fibroblasts or leukocytes by a 
standard method (51. A specific 192-bp segment of DNA from the a- 
GalA genomic gene was amplified by the PCR [6], using a GeneAmp 
DNA amplification reagent kit (Perkin Elmer Cetus, Norwalk, USA), 
genomic DNAs derived from various individuals as templates, and 
PFS 1 (5 ’ CAATGAAGCTGAGGAACCCA-3 ’ ) and PFS2 (5 ’ - 
GATGCAGGAATCTGGCTCTT-3 ’ ) oligonucleotides as primers. 
The PFS3 oligonucleotide (5 ’ -AGAACTGCATCTGGGCT3 ‘) was 
used as a sequencing primer. 
2.4. Site-directed mutagenesis and transient expression assay 
pMUP, pMUT and pMUG were constructed by site-directed 
mutagenesis [7], with single-stranded pAGF1 l-5 DNA as a template 
and, as primers, the three following oligonucleotides, which contain- 
ed single or double point mutations (underlined), 5’-GATTGGC- 
AAGGACGCCTACCATGGGCTGGC-3’, 5’-GATTGGCAAGG- 
ACG&ZTACCATGGGCTGGC-3’, and 5’-GATTGGCAAGGAC- 
GETACCATGGGCTGGC-3 ’ . Each EcoRI insert of pMUP, 
pMUT, pMUG and pAGF1 l-5 was inserted into the EcoRI site of the 
pBactE expression vector, and the products were named pBa4OP, 
pBa4OT, pBa4OG and pBa4OS, respectively. pBactE is a derivative of 
pBactS’ (Furuichi et al., unpublished; a gift from Furuichi) which car- 
ries the 5 ‘-flanking region and the first intron of the chick gene for 
,&actin [S], which contains the promoter and enhancer (see fig.JB). 
These plasmids were transiently introduced into FIS cells deficient 
in @-GalA activity by the calcium phosphate method [9]. a-GalA 
activity was determined by a standard method (lo], using 
4-methylumbelliferyl cu-D-galactoside (Sigma, St. Louis, USA) as 
substrate. 
3. RESULTS AND DISCUSSION 
3.1. Northern blotting analysis 
Poly(A) + RNAs from mutant FIS cells and wild-type 
NSF cells were analyzed by Northern blotting using an 
anti-sense probe (RAGl) that contained a sequence that 
is complementary to a-GalA mRNA (fig.1). A mouse 
EF2 gene probe was also used as a control. Only a single 
1.3-kb band of a-GalA mRNA was observed whether 
the poly(A) + RNA isolated from NSF cells or that from 
NSF FIS 
1.3kb - - a-GalA 
3.0kb - i - EF2 
Fig.1. Analysis by Northern blotting of cu-GalA mRNA. Poly(A)+ 
RNAs (2cg) prepared from wild-type NSF and mutant FIS cells were 
subjected to electrophoresis on an agarose gel, blotted onto a nylon 
membrane, and hybridized with the RAG1 probe ((Y-GalA gene pro- 
be, upper panel). The same membrane was also rehybridized with a 
Fig.2. Differences in nucleotide sequences between FIS mutant and 
wild-type cDNAs that encode cu-GalA. The triplet codons containing 
point mutations and the corresponding amino acid residues are 
shown. The numbers above and beneath the bars indicate the 
nucleotide numbers of a-GalA cDNA and the amino acid residue 
numbers of an c~-GalA precursor protein, respectively. The asterisks 
control probe for the EF2 gene (lower panel). indicate the nucleotide and amino acid substitutions. 
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FIS cells was analyzed. The intensities of both the band 
of cu-GalA mRNA and the band of EF2 mRNA, as a 
control in the preparation of FIS poly(A) + RNA were 
slightly stronger than those obtained with the prepara- 
tion of NSF poly(A)+ RNA. However, the intensity of 
the band of a-GalA mRNA normalized by reference to 
the intensity of the band of EF2 mRNA was almost the 
same in the two preparations of poly(A) + RNA, sug- 
gesting that the level of a-GalA mRNA was almost the 
same in both FIS and NSF cells. 
3.2. Sequence of the cDNA for the mutant a-GalA 
cloned from the patient 
We isolated the full-length cDNA AAGFll that en- 
coded the mutant cu-GalA from FIS cells, determined its 
nucleotide sequence, and found two nucleotide dif- 
ferences between the FIS mutant cDNA and the 
reported sequence of wild-type cDNA [2]: A-to-G and 
C-to-T nucleotide substitutions at nucleotide numbers 
24 and 118, respectively (fig.2). Although the former 
substitution was silent, the latter resulted in an amino 
acid substitution of Pro-40 by Ser. This missense muta- 
tion is located at the 9th amino acid residue of the 
mature a-GalA protein and on the first exon of the 
genomic gene. According to calculations by the Chou- 
Fasman program [ 111, the wild-type protein forms a fl- 
sheet structure and an a-helix at the regions of the 
amino acid residues from positions 38 to 40 and 43 to 
52, respectively (fig.3A,a), whereas the mutant protein 
forms a&sheet structure at the region of the amino acid 
residues from positions 39 to 52 (fig.3A,b). 
3.3. Transient expression assay of cu-GalA activity 
To determine whether the deficiency of a-GalA ac- 
tivity in the patient resulted from the amino acid 
substitution described above, we introduced two 
cDNAs that encoded the wild-type (pBa40P) and the 
mutant (pBa4OS) a-GalA, respectively (fig.3B), into 
FIS cells and assayed the enzymatic activity of the 
transfected cells (table 1). Mutant FIS cells showed only 
0.6% of the cu-GalA activity observed in wild-type NSF 
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Fig.3. Secondary structures of CY-GalA proteins expressed by pBactE expression plasmids that contain various c~-GalA cDNAs. (A) Secondary struc- 
tures of cu-GalA proteins. The region between amino acid residues 16 to 60 is shown. The coils and notches indicate ru-helices and@-sheet structures, 
respectively. a, wild-type protein with Pro-40; b, FIS mutant protein with Ser-40; c, mutant protein with Gly-40; d, mutant protein with Thr-40. 
The numbers indicate the positions of the amino acid residues. (B) Structures of pBactE plasmids that contain (~-calA cDNAs. Four different cy- 
GalA proteins: the wild-type protein witb Pro-4& a mutant protein with Ser-40 (FIS mutant); and two other mutant proteins with Thr-40 or Gly-40, 
were produced by the transient ransfection of FIS mutant cells with pBarlOP, pBa4OS, pBa4OT, and pBa4OG, respectively. The arrow indicates 
the orientation of the @-actin promoter. 
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Fig.4. PCR analysis of the tu_GalA gene for members of the famity of the patient with FD. (a) A 192-bp segment of DNA containing the point 
mutation found in the @&lA gene in FIS cells was amplified, using genomic DNAs prepared from NSF cells, FIS cells and from the leukocytes 
obtained from the members of the patient’s family (I-l, I-4, II-l, and II-2), as templates. The reaction mixture, which contained 100 pmol each 
of PSFl and PFS2 primers and 1 ,ug of genomic DNA in a GeneAmp cocktail (Perkin Elmer Cetus) was subjected to 30 temperature cycles which 
were composed of a I-min incubation at 93”C, a 2-min incubation at 5S°C, and another Z-min incubation at 72X!. The double-stranded reaction 
products were purified by el~trophoresis on acrylamide gels. The singIe-stranded DNA of the segment was prepared as described previously 161 
and then sequenced. Portions of the sequencing ladders for the DNA segments obtained from wild-type NSF cells, mutant FIS cells, and the 
leukocytes from I-4 (heterozygote) are shown. The arrowheads indicate the bands at nucleotide number 118. (b) Pedigree of the patient’s family. 
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Table 1 
Enzymatic activity of cu-GalA in transiently expressing cells 
Cell DNA 
transfected 
Type Enzymatic activity (nmol/h per 
of DNA mg protein) 
Mean + SE* % of 
NSF 
NSF None 30.7 * 0.74 100 
FIS None 0.19 + 0.02 0.6 
pBa40P wild-type 3120 + 712 10200 
pBa40S FIS mutant 1.14 f 0.01 3.7 
pBa40T mutant 1.06 * 0.14 3.5 
pBa4OG mutant 0.32 + 0.10 1.0 
*Enzymatic activity was determined in triplicate samples. FIS cells 
were plated 24 h before transfection at 3 x lo5 cells per 50 mm plastic 
dish that contained (r-MEM supplemented with 10% FCS. Plasmid 
DNAs were co-precipitated with calcium phosphate and added to the 
dishes at a dosage of 20 pg DNA/dish. After incubation at 37°C for 
3 h in an atmosphere of 5% COz, the precipitates were washed out, 
and then 0.4 ml of a solution of 15% glycerol in HBS (0.818% NaCl, 
0.594% Hepes, 0.02% NazHP04) were added to the dishes. After a 
1-min incubation at room temperature, the glycerol solution was 
removed and the cells were washed with cu-MEM. Then the cells were 
cultured for 48 h in (u-MEM supplemented with 10% FCS. The cells 
(about 5 x 104 cells) were dissociated by treatment with trypsin and 
EDTA and collected by low-speed centrifugation. After neutrahza- 
tion of trypsin by washing with (r-MEM supplemented with 10% FCS, 
rY-GalA activity was determined. 
cells. When FIS cells were transfected with pBa40S, the 
activity was six times higher than that observed in non- 
transfected FIS cells, but the value was only 3.7% of the 
activity observed in NSF cells. In contrast, when FIS 
cells were transfected with pBa4OP, the activity was 102 
times higher than that observed in NSF cells. These 
results indicate that the substitution of Pro-40 by Ser 
caused the deficiency of cr-GalA activity in the patient. 
In addition, the cY-GalA cDNA gene under the control 
of the @actin promoter was strongly expressed in 
human fibroblasts. 
Next, we designed two a-GalA cDNA constructs, 
pBa40T and pBa4OG, in which Pro-40 was replaced by 
Thr and Gly, respectively. According to calculations by 
the Chou-Fasman program, the protein with Gly-40 
(fig.3A,c) should have a gross secondary structure 
similar to that of the wild-type protein, whereas the pro- 
tein with Thr40 (fig.3A,d) should have a gross secon- 
dary structure similar to that of the FIS mutant protein. 
Irrespective of whether FIS cells were transfected with 
pBa40G or pBa40T, the cu-GalA activity observed in the 
transfectants was very low (only 1 .O% and 3.5% of that 
in NSF cells, respectively). These results suggest hat it 
is not the apparent secondary structure of the tu-GalA 
protein around the 40th amino acid residue, as 
predicted by the Chou-Fasman program, but it is 
Pro-40 per se that is critical for the appearance of en- 
zymatic activity. 
3.4. PCR analysis of the cu-GalA gene for members 
of the patient’s family 
To trace the transmission of the mutant cu-GalA gene 
among the members of the patient’s family, we analyz- 
ed genomic DNAs from the female members of the pa- 
tient’s family, two sisters (fig.4b, I-l and I-4) and two 
nieces (11-l and II-2), by PCR and subsequent sequenc- 
ing. We found that all the females examined had both 
the wild-type gene and the FIS mutant gene as hetero- 
zygotes (fig.4a, heterozygote). These results are consis- 
tent with the fact that each of these females, with the ex- 
ception of II-1 have suffered from some symptoms of 
FD. The nucleotide sequences determined by control 
PCR experiments with the genomic DNAs from NSF 
and FIS cells were consistent with those of the wild-type 
cDNA [2] and mutant cDNA determined by cloning 
(fig.4a, NSF and FIS). 
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